COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04527575 EpiVac LLC; VECTOR Ryzhikov AB, Infektsiia Immun, 2021 Full text Commentary |
Protein subunit |
EpiVacCorona |
Placebo |
RCTPhase 2 | Healthy adult SARS-CoV-2 infection-free volunteers in a single center in Russia. | N= 86 |
Some concerns Details |
|